What type of study is this?

This is a Systematic Review study.

November 30, 2025

The cost‐effectiveness of cystic fibrosis transmembrane conductance regulator modulators: A systematic review of economic evaluations

AFAndrea Katrin FaourVancouver Coastal Health ABAndrej Belančić IŠIda ŠtimacUniversity of Rijeka

Key Points

Health benefits of CFTR modulators include improved quality-adjusted life-years and reduced pulmonary exacerbations, despite high costs.
Cost-effectiveness ratios for modulators like ivacaftor vary significantly across regions, ranging from $536,472 in Scotland to $4,898,079 in Canada.
Economic evaluations were identified through systematic review of studies, utilizing methodologies and reporting standards for quality assessment.
Implications indicate a need for future studies to address affordability challenges in cystic fibrosis care and broaden economic evaluations.

Abstract

Cystic fibrosis (CF) is a life‐threatening genetic disorder affecting approximately 160 000 people worldwide. Mutations in the CF transmembrane conductance regulator (CFTR) gene cause progressive multi‐organ damage, particularly in the lungs. CFTR modulators have transformed CF care; however, their high costs raise concerns about cost‐effectiveness. This systematic review examined cost‐effectiveness studies of four CFTR modulators: ivacaftor (IVA), lumacaftor–ivacaftor (LUM‐IVA), tezacaftor–ivacaftor (TEZ‐IVA) and elexacaftor–tezacaftor–ivacaftor (ELX‐TEZ‐IVA). Ovid MEDLINE, Embase and government websites were searched for studies comparing modulators with standard care or each other. Study quality was assessed using the Consensus on Health Economic Criteria (CHEC) checklist and reporting quality using CHEERS 2022. A narrative synthesis was conducted and incremental cost‐effectiveness ratios (ICERs) were discussed. The review followed PRISMA guidelines and was registered with PROSPERO (CRD42024570006). Twenty‐nine studies yielded 34 ICERs (cost per quality‐adjusted life‐year QALY gained) across Canada, England, Ireland, Scotland, Wales and the United States. CFTR modulators produced significant clinical benefits, including improved QALYs and reduced pulmonary exacerbations, but were associated with extremely high costs, exceeding willingness‐to‐pay thresholds. IVA's ICERs ranged from US536 472/QALY in Scotland to US4 898 079/QALY in Canada, LUM‐IVA's from US378 503/QALY in Scotland to US7 504 825/QALY in Canada, TEZ‐IVA's from US635 325/QALY in Scotland to US1 657 332/QALY in the United States and ELX‐TEZ‐IVA's from US334 047/QALY in Ireland to US2 093 361/QALY in Canada. Sensitivity analyses indicated the need for substantial price reductions to be considered cost‐effective. CFTR modulators provide substantial health benefits but pose significant financial challenges. Future research should broaden economic evaluations, consider societal impacts and explore strategies to improve affordability and access.

Ask AI

Helpful

Bookmark

View Full Paper